Format

Send to

Choose Destination
J Oncol Pharm Pract. 2011 Dec;17(4):312-9. doi: 10.1177/1078155210380293. Epub 2010 Sep 7.

Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors.

Author information

1
Pharmacy Services, UK HealthCare, Lexington, KY, USA. aehitr2@uky.edu

Abstract

PURPOSE AND RELEVANCE: Chemotherapy-induced thrombocytopenia (CIT) can be a significant problem in patients with cancer, leading to numerous clinical complications. Understanding the types of patients at risk for these complications is essential to improve monitoring, counseling, and provide future targeted prophylaxis measures. Previous studies have limited prospective utility since they do not examine risk factors associated with complications from multi-agent regimens. This evaluation aims to identify the incidence and risk factors associated with clinical complications of CIT in patients receiving common chemotherapy regimens.

METHODS:

Retrospective evaluation of adult patients receiving first or second line regimens for the most common solid tumors associated with high rates (≥5%) of laboratory diagnosed thrombocytopenia. Patients were examined for clinically significant CIT (defined as platelet count <75,000 cells/µL as well as the presence of one of the following: bleeding, dose reduction/delay, platelet transfusion, or therapy cessation) and associated risk factors.

RESULTS:

About 254 patients receiving a total of 278 regimens were evaluated. The incidence of clinically significant CIT=10.1%; complications were most common in patients receiving cisplatin/gemcitabine for bladder cancer (57%), or carboplatin/gemcitabine (29%) or cisplatin/etoposide (18%) for lung cancer. Bladder cancer (OR=13.7 (2.89-64.7); p=0.001) and concurrent or recent infection (OR=3.8 (1.45-10.1); p=0.007) was found to increase the risk of clinical complications while smoking was found to have a protective effect (OR=0.17 (0.04-0.71)).

CONCLUSIONS:

The incidence of clinically significant CIT is most commonly seen in patients using cisplatin/gemcitabine for bladder cancer, or carboplatin/gemcitabine or cisplatin/etoposide for lung cancer. Further evaluation of these patients is warranted.

PMID:
20823048
DOI:
10.1177/1078155210380293
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center